Antibiotic Blujepa approved for urinary tract infections in women 12 and older
The U.S. Food and Drug Administration (FDA) on Tuesday approved a GSK drug for a common type of urinary tract infection (UTI) in women and adolescent girls.
The antibiotic, brand name Blujepa, is approved for women 12 and older to treat uncomplicated urinary tract infections, which are bacterial infections that also affect the lower urinary tract in healthy people.
Blujepa, whose price details have not yet been disclosed, is scheduled to be available in the U.S. in the second half of this year.
GSK said Blujepa, known chemically as gepotidacin, is designed to target the most common bacteria that cause urinary tract infections, such as E. coli. This drug also affects different parts of bacteria than most antibiotics, making it effective against organisms that are resistant to current treatments.
